Biocon's Board will meet on May 7, 2026, to approve audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026.
The Board will also consider recommending a dividend for the financial year, subject to its decision.
A closed trading window is in effect from April 1 to May 9, 2026, in compliance with insider trading regulations.
An earnings conference call for analysts and investors is scheduled for May 8, 2026, at 09:00 hrs IST.